At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 17 enrolled
Drug / intervention
MK-8527drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8527 Monotherapy in Anti-Retroviral Therapy (ART)-Naïve, HIV-1 Infected Participants
In Brief
A Phase 1 clinical trial evaluating MK-8527 for Human Immunodeficiency Virus and AIDS Virus. Completed, enrolled 17 participants across 1 site.
Detailed Summary
This study will evaluate the anti-retroviral activity of MK-8527 in HIV-1 infected, ART-naïve participants. The primary hypothesis is that MK-8527 has superior anti-retroviral activity compared to placebo, as measured by change from baseline in plasma HIV-1 ribonucleic acid (RNA) at 168 hours postdose.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuman Immunodeficiency Virus, AIDS Virus
CountriesRomania
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedAug 2018
Enrollment StartFeb 2019
Primary CompletionSep 2019
TodayJul 2026
First PostedAug 3, 2018
Enrollment StartFeb 11, 2019
Primary CompletionSep 26, 2019
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 7.9 years ago
Interventions
MK-8527drug
Single oral capsule